Unknown

Dataset Information

Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial.


ABSTRACT:

Introduction

The long-term efficacy and safety of donepezil 10 mg in patients with dementia with Lewy bodies (DLB) were investigated in a 52-week Phase 3 trial.

Methods

This 52-week study consisted of 16-week randomized placebo-controlled (RCT) and 36-week open-label extension phases. Of 142 DLB patients enrolled in the RCT phase (three arms: placebo, 5 mg, and 10 mg), 110 entered the extension phase. The placebo group of the RCT phase initiated active treatment at week 16, and the active groups maintained allocated treatment and dosages until week 24. After week 24, all patients received 10 mg. Dose reduction to 5 mg for safety concerns was allowed. Efficacy measures included Mini-Mental State Examination (MMSE) for cognitive function and Neuropsychiatric Inventory (NPI) fo

SUBMITTER: Mori E 

PROVIDER: S-EPMC4338564 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature